Search Clinical Trials in the European Union

1-2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
81-100 of 653 trials

Atopic Dermatitis in Children: Tralokinumab Treatment

We are studying whether a new treatment with tralokinumab and topical steroids helps children aged 2 to under 12 and infants aged 6 months to under 2 manage moderate-to-severe atopic dermatitis better than a placebo. The trial also looks at how this treatment affects daily life and skin health.

Atopic Dermatitis1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Efepoetin Alfa for Anemia in Chronic Kidney Disease on Dialysis

We are studying whether efepoetin alfa can effectively manage anemia in patients with chronic kidney disease on dialysis, compared to another treatment. This trial will also assess safety and quality of life for participants.

Anemia of Chronic Disease1-2 yearsConfirmation phase (III)>20 visitsNo PlaceboInvestigational MedicinesPartially RemoteHematologyNephrology

Breast Cancer-Related Lymphedema: Topical Tacrolimus Study

We are investigating whether a topical ointment can reduce swelling in patients with breast cancer-related lymphedema. This study compares the ointment to a placebo to see if it improves symptoms and quality of life.

Lymphedema1-2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteInternal MedicineOncology

Systemic Lupus Erythematosus: Upadacitinib Study

We are investigating whether the oral medication upadacitinib can improve symptoms in adults with moderate to severe systemic lupus erythematosus. The study will also monitor its safety over time compared to a placebo.

Systemic Lupus Erythematosus1-2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementRheumatology

Multiple Myeloma: JNJ-79635322 Study

We are testing a new medication for individuals with relapsed or refractory multiple myeloma or previously treated AL amyloidosis. The goal is to see how safe and effective this treatment is in humans.

Relapsed or Refractory Multiple MyelomaPreviously Treated AL Amyloidosis1-2 yearsSafety phase (I)HematologyOncology

Chronic Cutaneous Lupus Erythematosus: Anifrolumab Study

We are investigating whether anifrolumab can improve skin symptoms in adults with chronic cutaneous lupus erythematosus who haven't responded to other treatments. The study will compare its effects to a placebo over 24 weeks.

Cutaneous Lupus Erythematosus1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteDermatologyRheumatology

Advanced Breast Cancer: Lasofoxifene and Abemaciclib vs. Fulvestrant and Abemaciclib

We are studying two treatment combinations for men and women with advanced breast cancer and an ESR1 mutation. The goal is to see which combination helps patients live longer without disease progression.

Metastatic Breast Cancer1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Heart Failure and Obesity: Weight Loss with Semaglutide

We are investigating whether weight loss using semaglutide is more effective than a calorie-restricted diet in improving physical performance for patients with heart failure and obesity. The study also looks at quality of life and heart health impacts from both weight loss methods.

Heart Failure with Reduced Ejection FractionObesity1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesPartially RemoteCardiologyDiabetologyEndocrinology

Post-Menopausal Osteoporosis: BP16 vs. EU-Prolia

We are comparing a new treatment, BP16, to EU-Prolia for women with post-menopausal osteoporosis. The study looks at how well each treatment improves bone health and their safety.

Post-Menopausal Osteoporosis1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteEndocrinologyRheumatology

Pneumonia: TAD® Treatment Study

We are testing whether TAD®, an intravenous treatment, can help prevent heart injury in hospitalized patients with pneumonia. This study aims to evaluate its safety and effectiveness as an additional therapy.

Heart Injury from Pneumonia1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteCardiologyInternal MedicinePulmonology

Dapagliflozin for Heart Health in Amyloid Transthyretin Cardiac Amyloidosis

We are studying how dapagliflozin may improve exercise capacity and quality of life for patients with ATTR-CA. This trial will also look at its safety and other health markers.

Cardiac Amyloidosis1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyInternal Medicine

Chronic Pancreatitis: Metamizole for Pain Relief

We are investigating whether adding metamizole to existing pain treatments helps reduce pain in patients with chronic pancreatitis diagnosed within the last three years.

Chronic Pancreatitis1-2 yearsMonitoring phase (IV)Standard MedicinesGastroenterologyInternal Medicine

Alzheimer's Disease: KarXT Medication Study

We are examining how well the medication KarXT is tolerated over a long period in people with psychosis related to Alzheimer's disease. This study aims to ensure the safety of this treatment for participants.

Psychosis Associated with Alzheimer's Disease1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyPsychiatry

Advanced Solid Tumors: T3P-Y058-739 Treatment

We are testing a new genetically-modified bacterium for patients with advanced solid tumors. This study aims to explore its safety and potential benefits in treating cancer.

Solid Tumors1-2 yearsSafety phase (I)Efficacy phase (II)Oncology

Montelukast for Mild-Moderate Parkinson’s Disease

We are studying whether Montelukast can slow disease progression in people with mild to moderate Parkinson’s disease. The trial also examines its effects on symptoms and potential side effects.

Parkinson's Disease1-2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesNeurology

Pleural Mesothelioma: New Chemotherapy and Immunotherapy Study

We are exploring a new treatment combining chemotherapy and immunotherapy for patients with inoperable pleural mesothelioma. The study will evaluate treatment completion rates, side effects, and overall quality of life.

Inoperable Pleural Mesothelioma1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Dupilumab for Young Children with Uncontrolled Asthma

We are studying whether dupilumab can help reduce severe asthma attacks in children aged 2 to under 6 years. The trial will also evaluate the safety and tolerability of this treatment.

Asthma and Wheezing1-2 yearsConfirmation phase (III)Standard MedicinesPartially RemoteAllergologyPediatricsPulmonology

CMV Prevention in Lung Transplant Recipients: Letermovir Study

We are studying whether letermovir can better prevent CMV infection in lung transplant recipients compared to standard treatment with valganciclovir. This research may help improve care for patients at risk of CMV disease.

Lung Transplant Patients (D+/R-)1-2 yearsEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteInfectious DiseasesPulmonology

GTX-11: Safety Study in Healthy Volunteers

We are testing a new medication called GTX-11 to see how safe it is and how the body handles it. Healthy adults are participating to help us understand its effects.

Pulmonary Fibrosis1-2 yearsSafety phase (I)Pulmonology

HER2-Positive Solid Tumors: Disitamab Vedotin Study

We are studying a new treatment called disitamab vedotin for adults with advanced solid tumors that express HER2 and have been previously treated. The trial aims to evaluate its effectiveness and safety.

Ovarian CancerHead and Neck CancerEndometrial Cancer1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology